Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. by Martine Humbert, Nathalie Castéran, Sébastien Letard, Katia Hanssens, Juan Iovanna, Pascal Finetti, François Bertucci, Thomas Bader, Colin D Mansfield, Alain Moussy, Olivier Hermine, Patrice Dubreuil

Get full text

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis by Jesus S. Mora, Walter G. Bradley, Delia Chaverri, María Hernández-Barral, Javier Mascias, Josep Gamez, Gisella M. Gargiulo-Monachelli, Alain Moussy, Colin D. Mansfield, Olivier Hermine, Albert C. Ludolph

Get full text

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial by Bruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine, Magda Tsolaki, for the AB09004 Study Group Investigators

Get full text

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial by Bruno Dubois, Jesús López‑Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine, Magda Tsolaki, for the AB09004 Study Group Investigators

Get full text

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. by Patrice Dubreuil, Sébastien Letard, Marco Ciufolini, Laurent Gros, Martine Humbert, Nathalie Castéran, Laurence Borge, Bérengère Hajem, Anne Lermet, Wolfgang Sippl, Edwige Voisset, Michel Arock, Christian Auclair, Phillip S Leventhal, Colin D Mansfield, Alain Moussy, Olivier Hermine

Get full text